Comparing Data for Capecitabine After Neoadjuvant Chemotherapy in TNBC

January 16, 2019
Carlos L. Arteaga, MD

Carlos L. Arteaga, MD, discusses the use of capecitabine after neoadjuvant chemotherapy in patients with triple-negative breast cancer.

Carlos L. Arteaga, MD, director of the Simmons Comprehensive Cancer Center at UT Southwestern Medical Center, discusses the use of capecitabine after neoadjuvant chemotherapy in patients with triple-negative breast cancer (TNBC).

In the phase III GEICAM/CIBOMA trial, there was not an improvement found in progression-free survival (PFS) in the experimental arm as compared to those randomized to observation. A subgroup analysis in this study showed there was improvement in PFS in patients with nonbasal TNBC, says Arteaga.